Akouos (Akouos) Capex-to-Operating-Income : 0.00 (As of Sep. 2022)

View and export this data going back to 2020. Start your Free Trial

What is Akouos Capex-to-Operating-Income?

Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.

Akouos's Capital Expenditure for the three months ended in Sep. 2022 was $-2.60 Mil. Its Operating Income for the three months ended in Sep. 2022 was $-20.20 Mil.

GuruFocus do not calculate Capex-to-Operating-Income if the Operating Income is negative.

Akouos Capex-to-Operating-Income Historical Data

The historical data trend for Akouos's Capex-to-Operating-Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Akouos Capex-to-Operating-Income Chart

Akouos Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Capex-to-Operating-Income

Akouos Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22
Capex-to-Operating-Income	Get a 7-Day Free Trial											-	-	-	-	-

Competitive Comparison of Akouos's Capex-to-Operating-Income

For the Biotechnology subindustry, Akouos's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Akouos's Capex-to-Operating-Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Akouos's Capex-to-Operating-Income distribution charts can be found below:

* The bar in red indicates where Akouos's Capex-to-Operating-Income falls into.

Akouos Capex-to-Operating-Income Calculation

Akouos's Capex-to-Operating-Income for the fiscal year that ended in Dec. 2021 is calculated as

Capex-to-Operating-Income	=	- Capital Expenditure	/	Operating Income
	=	- (-9.019)	/	-86.821
	=	N/A

Akouos's Capex-to-Operating-Income for the quarter that ended in Sep. 2022 is calculated as

Capex-to-Operating-Income	=	- Capital Expenditure	/	Operating Income
	=	- (-2.603)	/	-20.204
	=	N/A

Akouos (NAS:AKUS) Capex-to-Operating-Income Explanation

Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.

Akouos Capex-to-Operating-Income Related Terms

Thank you for viewing the detailed overview of Akouos's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Akouos (Akouos) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Akouos Inc (NAS:AKUS) » Definitions » Capex-to-Operating-Income

Comparable Companies

Traded in Other Exchanges

N/A

Address

645 Summer Street, Suite 200, Boston, MA, USA, 02210

Website

https://www.akouos.com

Akouos Inc is a genetic medicine company focused on developing gene therapies that restore, improve, and preserve hearing. The company is involved in developing potential genetic medicines for a variety of inner ear disorders.

Executives

Kearny Acquisition Corp	10 percent owner	LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Lilly Eli & Co	10 percent owner	LILLY CORPORATE CENTER, DROP CODE 1094, INDIANAPOLIS IN 46285
Jennifer Anne Wellman	officer: Chief Operating Officer	C/O AKOUOS, INC., 645 SUMMER STREET, SUITE 200, BOSTON MA 02210
Sachiyo Minegishi	officer: Chief Financial Officer	C/O AKOUOS, INC., 645 SUMMER STREET, SUITE 200, BOSTON MA 02210
5am Ventures V, L.p.	10 percent owner	2200 SAND HILL ROAD, SUITE 110, MENLO PARK CA 94025
Kush Parmar	director, 10 percent owner	C/O 5AM VENTURES, 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
Carmen Chang	10 percent owner	2855 SAND HILL ROAD, MENLO PARK CA 94025
Maha Katabi	10 percent owner	SOFINNOVA INVESTMENTS, 3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025
Sofinnova Venture Partners X, L.p.	10 percent owner	3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025
Pivotal Bioventure Partners Fund I G.p., L.p.	10 percent owner	501 SECOND STREET, SUITE 200, SAN FRANCISCO CA 94107
New Enterprise Associates 16, L.p.	10 percent owner	1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Paul Edward Walker	10 percent owner	1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Ecor1 Capital, Llc	10 percent owner	357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Cormorant Asset Management, Lp	10 percent owner	200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Heather Preston	director, 10 percent owner	C/O TPG GLOBAL, LLC, 301 COMMERCE STREET, FORT WORTH TX 76102